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Revised Definitions of Invasive Fungal Disease
from the European Organization for Research
and Treatment of Cancer/Invasive Fungal Infections
Cooperative Group and the National Institute
of Allergy and Infectious Diseases Mycoses Study
Group (EORTC/MSG) Consensus Group
Ben De Pauw,a Thomas J. Walsh,a J. Peter Donnelly,a David A. Stevens, John E. Edwards, Thierry Calandra,
Peter G. Pappas, Johan Maertens, Olivier Lortholary, Carol A. Kauffman, David W. Denning, Thomas F. Patterson,
Georg Maschmeyer, Jacques Bille, William E. Dismukes, Raoul Herbrecht, William W. Hope, Christopher C. Kibbler,
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Theoklis Zaoutis, and John E. Bennettb
Background. Invasive fungal diseases are important causes of morbidity and mortality. Clarity and uniformity
in defining these infections are important factors in improving the quality of clinical studies. A standard set of
definitions strengthens the consistency and reproducibility of such studies.
Methods. After the introduction of the original European Organization for Research and Treatment of Cancer/
Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses
Study Group (EORTC/MSG) Consensus Group definitions, advances in diagnostic technology and the recognition
of areas in need of improvement led to a revision of this document. The revision process started with a meeting
of participants in 2003, to decide on the process and to draft the proposal. This was followed by several rounds
of consultation until a final draft was approved in 2005. This was made available for 6 months to allow public
comment, and then the manuscript was prepared and approved.
Results. The revised definitions retain the original classifications of “proven,” “probable,” and “possible”
invasive fungal disease, but the definition of “probable” has been expanded, whereas the scope of the category
“possible” has been diminished. The category of proven invasive fungal disease can apply to any patient, regardless
of whether the patient is immunocompromised, whereas the probable and possible categories are proposed for
immunocompromised patients only.
Conclusions. These revised definitions of invasive fungal disease are intended to advance clinical and epide-
miological research and may serve as a useful model for defining other infections in high-risk patients.
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zation for Research and Treatment of Cancer/Invasive
Fungal Infections Cooperative Group (EORTC) and the
National Institute of Allergy and Infectious Diseases
Mycoses Study Group (MSG) published standard def-
initions for invasive fungal infections for clinical and
epidemiological research [1]. These definitions were de-
veloped to facilitate the identification of reasonably ho-
mogeneous groups of patients for clinical and epide-
miologic research, to help design clinical trials to
evaluate new drugs and management strategies, and,
last but not least, to foster communication between
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international researchers. The definitions assigned 3 levels of
probability to the diagnosis of invasive fungal infection that
develops in immunocompromised patients with cancer and in
hematopoietic stem cell transplant recipients—namely,
“proven,” “probable,” and “possible” invasive fungal infection.
The definitions established a formal framework for defining
invasive fungal infection with a variable certainty of diagnosis.
Proven invasive fungal infection required only that a fungus
be detected by histological analysis or culture of a specimen of
tissue taken from a site of disease; in the case of Cryptococcus
neoformans, detection of capsular antigen in CSF or a positive
result of an India ink preparation of CSF was considered suf-
ficient to establish a diagnosis of proven cryptococcosis. By
contrast, probable and possible invasive fungal infections
hinged on 3 elements—namely, a host factor that identified the
patients at risk, clinical signs and symptoms consistent with
the disease entity, and mycological evidence that encompassed
culture and microscopic analysis but also indirect tests, such
as antigen detection. These EORTC/MSG Consensus Group
definitions have been used in major trials of antifungal drug
efficacy, in strategy trials [2–6], for the formulation of clinical
practice guidelines [7], for validation of diagnostic tests [8–
13], and for performance of epidemiologic studies [14].
The previously published definitions were not without their
shortcomings. For instance, the original category of possible
invasive fungal infection allowed too many dubious cases to
be included, particularly those involving neutropenia, nonspe-
cific pulmonary infiltrates, and persistent fever refractory to
broad-spectrum antibiotics but with no evidence of invasive
fungal infection [15]. These cases may represent patients at
higher risk of invasive fungal infection but are quite different
from the cases, also defined as possible cases, for which more
specific pulmonary abnormalities, such as a halo or air-crescent
sign characteristic of invasive aspergillosis, were present. In-
deed, the definitions were modified to allow enrollment of sim-
ilar cases into clinical trials, because they are considered to
represent likely invasive fungal disease even without supporting
mycological evidence [2, 16]. This pragmatic approach solved
the problem of recruitment of representative cases, but it clearly
highlighted the need to refine further the definitions, to dis-
tinguish dubious cases from the more likely cases when my-
cological evidence was not forthcoming. The growing body of
evidence regarding the value of high-resolution CT of chest and
abdomen [17] and of indirect diagnostic tests—such as the
detection of galactomannan in body fluids other than serum
and plasma, of b-d-glucan in serum, and of fungal DNA in
body fluids by PCR—provided additional incentive to review
the definitions [18, 19]. The original definitions were also re-
stricted to patients with cancer and to recipients of hemato-
poietic stem cell transplants; however, invasive fungal infections
are known to affect other populations, including recipients of
solid-organ transplants and patients with primary immuno-
deficiencies (e.g., chronic granulomatous disorder) [20, 21].
Finally, it was considered appropriate to explore the possibility
of formulating specific criteria for diseases caused by less com-
mon fungal pathogens.
REVISION PROCESS
The EORTC/MSG Consensus Group met in Chicago, Illinois,
on 14 September 2003 during the 43rd Annual Interscience
Conference on Antimicrobial Agents and Chemotherapy
(ICAAC) and included 13 members from the EORTC and 17
from the MSG. J. Powers also participated for the US Food
and Drug Administration (FDA), and there were 5 observers
from 4 pharmaceutical companies (J. Rex [Astra Zeneca], C.
Sable [Merck], M. Bresnik [Gilead], and G. Triggs and A. Ba-
ruch [Pfizer]). B.d.P. and T.J.W. were confirmed as joint chairs,
and J.P.D. was designated as secretary for the group. Three
subcommittees were appointed to prepare proposals for mold
infection, candidiasis, and endemic mycoses. The proposals
were collated by the secretary, who integrated them into a gen-
eral framework. They were then circulated by electronic mail
to all group members. The ensuing comments again were cen-
trally combined for a subsequent round of electronic consul-
tation. The remaining issues that appeared difficult to solve by
the electronic route were addressed in open meetings during
the 15th European Congress of Clinical Microbiology and In-
fectious Disease in Copenhagen, Denmark, and the 45th Annual
ICAAC in Washington, DC. A majority vote was decisive when
a consensus among the members could not be achieved. The
final draft was made available to the wider community for
comment at the Doctor Fungus Web site [22] and The Asper-
gillus Web site [23]. Thereafter, the manuscript was prepared
and was circulated among all group members for their final
approval.
At the first meeting, all group members agreed to the need
to refine and revise the definitions. It was also agreed unani-
mously that the definition set should remain easily reproducible
and should offer the opportunity for a reasonable comparison
of future data sets with data sets that had been collected in
clinical trials that involved patients with proven and probable
invasive fungal infections according to the original definitions.
Finally, the group set out to reexamine the feasibility of using
the definitions for treatment purposes, to devise a means of
extending their applicability to other patient groups, to review
the relevance of the findings obtained from studies based on
the definitions for clinical practice, and to attempt to incor-
porate all the available laboratory tests and imaging techniques
into the definitions.
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REVISED DEFINITIONS
The term “invasive fungal disease” (IFD) was adopted to reflect
more accurately the notion that we are dealing with a disease
process caused by fungal infection. An adequate diagnostic eval-
uation of the infectious disease process, to exclude an alter-
native etiology, was deemed to be a necessary prerequisite to
classify it as an IFD. The group reaffirmed that the definitions
should be used only to assist in research and that the integrity
of the original definitions with the classifications of proven,
probable, and possible IFD would be preserved (tables 1–3).
Infections caused by Pneumocystis jiroveci are not included. The
criteria for proven and probable IFD (tables 1 and 2) were
modified to reflect advances in indirect tests, whereas the cat-
egory of possible IFD (table 3) was revised to include only cases
that are highly likely to be caused by a fungal etiology, although
mycological evidence is lacking. Hence, the definitions of prob-
able and possible IFD were based on the same 3 elements as
were the original definitions: host factors, clinical manifesta-
tions, and mycological evidence.
Host factors are not synonymous with risk factors but are
characteristics by which individuals predisposed to acquire IFD
can be recognized. Consequently, the presence of fever was
removed as a host factor because it represents a clinical feature,
not a host factor, and is nonspecific for IFD. The host factors
were extended to receipt of a solid-organ transplant, hereditary
immunodeficiencies, connective tissue disorders, and receipt of
immunosuppressive agents—for example, corticosteroids or T
cell immunosuppressants, such as calcineurin inhibitors, anti–
TNF-a drugs, anti-lymphocyte antibodies, or purine analogues.
The distinction between “minor” and “major” clinical criteria
was abandoned in favor of more-characteristic and objectively
verifiable evidence, such as the findings on medical imaging
that indicated a disease process consistent with IFD by use of
a standardized glossary of definitions. For example, in the case
of chest CT imaging to categorize pulmonary lesions, the vast
majority of immunocompromised patients with invasive pul-
monary aspergillosis have focal rather than diffuse pulmonary
infiltrates and present with at least 1 macronodule, with or
without a halo sign [24]. These infections can also manifest as
wedge-shaped infiltrates and segmental or lobar consolidation.
Although none of the imaging findings is pathognomonic for
IFD, the observation that, in the appropriate patient popula-
tion, the outcome of antifungal therapy did not differ between
febrile patients with nodular lesions and patients with myco-
logical evidence of an IFD supports the use of this clinical
criterion [17]. A similar consideration applies to patients with
lesions on CT or ultrasound that are regarded as typical for
chronic disseminated candidiasis. In the original definitions,
patients with such lesions were defined as having probable he-
patosplenic candidiasis without any need for mycological sup-
port. In the revised definitions, such cases are classified as pos-
sible IFD, thereby retaining the consistency of the definitions
and preserving the distinction between probable IFD and pos-
sible IFD. For a patient with appropriate host factors and clin-
ical evidence of pulmonary disease, bronchoalveolar lavage fluid
that yields Aspergillus, Zygomycetes, Fusarium, or Scedosporium
species or other pathogenic molds would constitute mycological
support and would allow the case to be classified as probable
pulmonary IFD.
As with the original definitions, indirect tests were considered
for inclusion only if they were validated and standardized. Fur-
thermore, because commercial tests for diagnostic use had to
provide criteria for interpretation to gain approval, it was de-
cided to rely entirely on the thresholds recommended by the
manufacturer. On the basis of recent studies, the Platelia As-
pergillus galactomannan EIA could be applied to CSF and bron-
choalveolar lavage fluid, as well as plasma and serum. The b-
d-glucan assay also was included as a marker for probable IFD,
because this test detects other species of fungi besides Asper-
gillus, and a commercial test for it (Fungitell assay; Associates
of Cape Cod) has been approved by the FDA. By contrast,
molecular methods of detecting fungi in clinical specimens,
such as PCR, were not included in the definitions because there
is as yet no standard, and none of the techniques has been
clinically validated.
THE CATEGORIES
Proven IFD. There was general agreement that the category
of proven IFD should be retained, requiring proof of IFD by
demonstration of fungal elements in diseased tissue for most
conditions (table 1). Revisions were made to this category to
reflect advances in indirect assays that are highly specific for
the infection being detected. By its very nature, this category
is likely to be valid irrespective of host factors or clinical fea-
tures. Individual IFD entities—for example, proven aspergil-
losis—require culture and identification. Failing this, the dis-
ease is designated as proven mold IFD (table 1). The histological
appearance of the endemic dimorphic fungi, Histoplasma cap-
sulatum, as small intracellular budding yeasts; Coccidioides spe-
cies as spherules; Paracoccidioides brasiliensis as large yeasts with
multiple daughter yeasts in a “pilot-wheel configuration”; and
Blastomyces dermatitidis as thick-walled, broad-based budding
yeasts is sufficiently distinctive to permit a definitive diagnosis
(table 3). H. capsulatum variety capsulatum resembles Candida
glabrata or Leishmania species in tissue but can be distinguished
from them by characteristic histological features of granulo-
matous inflammation in histoplasmosis in some patient groups
and by staining with silver, which shows staining for the fungi
but not for Leishmania species.
The category of proven IFD was modified to reflect advances
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Table 2. Criteria for probable invasive fungal disease except for endemic mycoses.
Host factorsa
Recent history of neutropenia (!0.5  109 neutrophils/L [!500 neutrophils/mm3] for 110 days) temporally related to the
onset of fungal disease
Receipt of an allogeneic stem cell transplant
Prolonged use of corticosteroids (excluding among patients with allergic bronchopulmonary aspergillosis) at a mean
minimum dose of 0.3 mg/kg/day of prednisone equivalent for 13 weeks
Treatment with other recognized T cell immunosuppressants, such as cyclosporine, TNF-a blockers, specific monoclonal
antibodies (such as alemtuzumab), or nucleoside analogues during the past 90 days
Inherited severe immunodeficiency (such as chronic granulomatous disease or severe combined immunodeficiency)
Clinical criteriab
Lower respiratory tract fungal diseasec
The presence of 1 of the following 3 signs on CT:
Dense, well-circumscribed lesions(s) with or without a halo sign
Air-crescent sign
Cavity
Tracheobronchitis
Tracheobronchial ulceration, nodule, pseudomembrane, plaque, or eschar seen on bronchoscopic analysis
Sinonasal infection
Imaging showing sinusitis plus at least 1 of the following 3 signs:
Acute localized pain (including pain radiating to the eye)
Nasal ulcer with black eschar
Extension from the paranasal sinus across bony barriers, including into the orbit
CNS infection
1 of the following 2 signs:
Focal lesions on imaging
Meningeal enhancement on MRI or CT
Disseminated candidiasisd
At least 1 of the following 2 entities after an episode of candidemia within the previous 2 weeks:
Small, target-like abscesses (bull’s-eye lesions) in liver or spleen
Progressive retinal exudates on ophthalmologic examination
Mycological criteria
Direct test (cytology, direct microscopy, or culture)
Mold in sputum, bronchoalveolar lavage fluid, bronchial brush, or sinus aspirate samples, indicated by 1 of the following:
Presence of fungal elements indicating a mold
Recovery by culture of a mold (e.g., Aspergillus, Fusarium, Zygomycetes, or Scedosporium species)
Indirect tests (detection of antigen or cell-wall constituents)e
Aspergillosis
Galactomannan antigen detected in plasma, serum, bronchoalveolar lavage fluid, or CSF
Invasive fungal disease other than cryptococcosis and zygomycoses
b-d-glucan detected in serum
NOTE. Probable IFD requires the presence of a host factor, a clinical criterion, and a mycological criterion. Cases that meet the criteria for a
host factor and a clinical criterion but for which mycological criteria are absent are considered possible IFD.
a Host factors are not synonymous with risk factors and are characteristics by which individuals predisposed to invasive fungal diseases can be
recognized. They are intended primarily to apply to patients given treatment for malignant disease and to recipients of allogeneic hematopoietic
stem cell and solid-organ transplants. These host factors are also applicable to patients who receive corticosteroids and other T cell suppressants
as well as to patients with primary immunodeficiencies.
b Must be consistent with the mycological findings, if any, and must be temporally related to current episode.
c Every reasonable attempt should be made to exclude an alternative etiology.
d The presence of signs and symptoms consistent with sepsis syndrome indicates acute disseminated disease, whereas their absence denotes
chronic disseminated disease.
e These tests are primarily applicable to aspergillosis and candidiasis and are not useful in diagnosing infections due to Cryptococcus species
or Zygomycetes (e.g., Rhizopus, Mucor, or Absidia species). Detection of nucleic acid is not included, because there are as yet no validated or
standardized methods.
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Table 3. Criteria for the diagnosis of endemic mycoses.
Diagnosis and criteria
Proven endemic mycosis
In a host with an illness consistent with an endemic mycosis, 1 of the following:
Recovery in culture from a specimen obtained from the affected site or from blood
Histopathologic or direct microscopic demonstration of appropriate morphologic forms with a truly distinctive appearance
characteristic of dimorphic fungi, such as Coccidioides species spherules, Blastomyces dermatitidis thick-walled broad-
based budding yeasts, Paracoccidioides brasiliensis multiple budding yeast cells, and, in the case of histoplasmosis, the
presence of characteristic intracellular yeast forms in a phagocyte in a peripheral blood smear or in tissue macrophages
For coccidioidomycosis, demonstration of coccidioidal antibody in CSF, or a 2-dilution rise measured in 2 consecutive
blood samples tested concurrently in the setting of an ongoing infectious disease process
For paracoccidioidomycosis, demonstration in 2 consecutive serum samples of a precipitin band to paracoccidioidin con-
currently in the setting of an ongoing infectious disease process
Probable endemic mycosis
Presence of a host factor, including but not limited to those specified in table 2, plus a clinical picture consistent with en-
demic mycosis and mycological evidence, such as a positive Histoplasma antigen test result from urine, blood, or CSF
NOTE. Endemic mycoses includes histoplasmosis, blastomycosis, coccidioidomycosis, paracoccidioidomycosis, sporotrichosis, and infection
due to Penicillium marneffei. Onset within 3 months after presentation defines a primary pulmonary infection. There is no category of possible
endemic mycosis, as such, because neither host factors nor clinical features are sufficiently specific; such cases are considered to be of value too
limited to include in clinical trials, epidemiological studies, or evaluations of diagnostic tests.
in our understanding of Coccidioides serological characteristics.
Consequently, the presence of coccidioidal antibody in CSF was
considered to be sufficient to fulfill the criteria for proven coc-
cidioidomycosis. Similarly, the presence of capsular antigen in
CSF was considered to be sufficiently distinctive to establish a
diagnosis of disseminated cryptococcosis [25]. Urinary Histo-
plasma antigen supports a diagnosis of probable endemic my-
cosis, in conjunction with appropriate host and clinical criteria
(table 3), but cannot be considered sufficient evidence of proven
histoplasmosis, because Histoplasma antigen is also found in
urine and serum of patients with coccidioidomycosis and blas-
tomycosis [26].
Probable IFD. Cases of probable IFD require that a host
factor, clinical features, and mycological evidence be present,
as outlined in tables 2 and 3.
Possible IFD. The category of possible IFD was retained
but was defined more strictly to include only those cases with
the appropriate host factors and with sufficient clinical evidence
consistent with IFD but for which there was no mycological
support (table 2). However, this category was not considered
appropriate for endemic mycosis, because host factors and clin-
ical features are not sufficiently specific and because such cases
would be of value too limited to include in clinical trials, ep-
idemiological studies, or evaluations of diagnostic tests.
COMMENTS
Implications of the revised category of possible IFD. After
enrollment into an interventional or diagnostic study, every
effort should be made to upgrade the certainty of diagnosis for
patients with possible IFD to the category of proven or probable
IFD. These definitions may be applied at different times during
the period of risk. For example, although a case might not meet
the definition of possible, probable, or proven IFD at the be-
ginning of a period of high risk, during which prophylaxis is
given, the case may continue to evolve, such that the criteria
may be met later.
The overrepresentation of dubious cases that resulted from
the application of the original definitions made it imperative
to redress the balance and to capture more patients with a
higher probability of IFD while excluding patients who are
unlikely to have invasive mycosis. Some members even argued
that the category of possible IFD, as defined in the original set
of definitions, should be abolished altogether. However, such
a decision would reduce dramatically the number of candidates
eligible for clinical studies of fungal pneumonia, making ran-
domized trials nearly impossible to conduct. The corollary of
retaining a better-defined category of possible IFD, to reduce
the number of doubtful cases, was that greater emphasis was
placed on mycological evidence for the categories of proven
and probable IFD. This allows the category of possible IFD to
be reserved for clinical manifestations fully consistent with fun-
gal etiology but for which there is no mycological evidence
available, although a reasonable attempt has been made to ex-
clude an alternative etiology.
Non–culture-based diagnostic tests. There was much dis-
cussion about indirect mycological tests, especially assays for
detection of antigen and b-d-glucan. Since the first definitions
were published [1], the FDA has approved the Aspergillus gal-
actomannan EIA and, more recently, the assay for b-d-glucan,
on the grounds that they were standardized, were validated, are
available, and are fit to convey useful information [8, 19, 27].
However, controversy arose about the interpretation of the in-
dex for the galactomannan assay, which was originally set at
1.5 and was applied in Europe but which was lowered to 0.5
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after review by the FDA. This cutoff value has been shown
recently to improve the overall performance of the test for adult
hematology patients [28]. Because the issue remains conten-
tious, the decision was made to place the onus on the man-
ufacturers of commercial tests and to adopt whatever threshold
values they recommend.
We had hoped that nucleic acid–detection tests, such as PCR,
would have improved enough to incorporate the results of these
tests into the definitions. However, standardization and vali-
dation have not yet been attained for these platforms.
Limitations of the revised definitions. The revised defi-
nitions apply to immunocompromised patients but not nec-
essarily to critically ill patients in the intensive care unit who,
nonetheless, may develop possible or probable IFD [29]. The
group recognized this as an omission but was unable to find
a sufficient basis for identifying the appropriate host factors,
even though there may be mycological evidence, such as re-
covery of Aspergillus species from bronchial secretions or a
positive b-d-glucan test result. The group, therefore, concluded
that the body of evidence supporting a diagnosis other than
proven IFD is not sufficiently mature at present.
The definitions are not a substitute for complete clinico-
pathologic descriptions and classifications of IFD, as have been
published recently for aspergillosis [21]. The failure to meet
the criteria for IFD does not mean that there is no IFD, only
that there is insufficient evidence to support the diagnosis. This
is the most compelling reason for not employing these defi-
nitions in daily clinical practice.
We anticipate that the field of diagnosis will continue to
evolve, so that there will come a time when the definitions may
be formally evaluated for their sensitivity and specificity. Until
then, additional revisions of the present set of definitions are
likely, but they should be contemplated carefully. The words
and phrases chosen here were selected on the basis of extensive
debate and discussion. Seemingly, slight changes may have un-
expectedly profound consequences in the design, implemen-
tation, and interpretation of clinical trials.
These revised definitions of IFD categories are intended to
advance clinical and epidemiological research and, as such, may
serve as a useful model for defining other infections in high-
risk patients. The definitions are not meant to be used to guide
clinical practice but must be applied consistently if they are to
continue to achieve their primary goal of fostering commu-
nication, furthering our understanding of the epidemiology and
evolution of IFD, and facilitating our ability to test the efficacy
of therapeutic regimens and strategies.
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